Molecular interaction fields (MIFs) to predict lipophilicity and ADME profile of antitumor Pt(II) complexes

Pharmaceutical Research

Volumn 28, Issue 3, 2011, Pages 640-646

  Caron, Giulia ^a   Ravera, Mauro ^b   Ermondi, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

ADME prediction; distribution volume; lipophilicity; Molecular Interaction Fields; Pt(II) complexes

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ALGORITHM; ARTICLE; CALIBRATION; CHEMICAL MODIFICATION; CHROMATOGRAPHY; CONFORMATION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG STRUCTURE; HYDROPHILICITY; HYDROPHOBICITY; LIPOPHILICITY; MOLECULAR INTERACTION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING;

ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; LIPIDS; MODELS, MOLECULAR; PLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS;

EID: 79952484476     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0317-1     Document Type: Article

References (31)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573-84. (Pubitemid 47106628)
2. Kelland L, Farrell N. Platinum-based drugs in cancer therapy. Totowa: Humana Pre; 2000.
3. Gabano E, Ravera M, Osella D. The drug targeting and delivery approach applied to Pt-antitumour complexes. A coordination point of view. Curr Med Chem. 2009;16(34):4544-80.
4. Gaviraghi G, Barnaby RJ, Pellegatti M. In: Testa B, van de Waterbeemd H, Folkers G, Guy R, editors. Pharmacokinetic challenges in lead optimization. Zurich: Wiley-VHCA; 2001. p. 3-14.
5. Tetko IV, Jaroszewicz I, Platts JA, Kuduk-Jaworska J. Calculation of lipophilicity for Pt(II) complexes: experimental comparison of several methods. J Inorg Biochem. 2008;102(7):1424-37.
6. Nasal A, Siluk D, Kaliszan R. Chromatographic retention parameters in medicinal chemistry and molecular pharmacology. Curr Med Chem. 2003;10:381-426. (Pubitemid 36221571)
7. Martel S, Guillarme D, Henchoz Y, Galland A, Veuthey J, Rudaz S, et al. Chromatographic approaches for measuring log P. In: Mannhold R, editor. Molecular drug properties. Measurement and prediction. Darmstadt: Wiley-VCH; 2008. p. 331-55.
8. Valko K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J Chromatogr A. 2004;1037(1-2):299-310. (Pubitemid 38591346)
9. Boobbyer DN, Goodford PJ, Mcwhinnie PM, Wade RC. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J Med Chem. 1989;32:1083-94. (Pubitemid 19122160)
10. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem. 1985;28:849-57. (Pubitemid 15012490)
11. Wade RC, Goodford PJ. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds. J Med Chem. 1993;36:148-56.
12. Cruciani G, Mannhold R, Kubinyi H, Folkers G. Molecular interaction fields. Applications in drug discovery and ADME prediction. Zurich: Wiley-VCH; 2006.
13. Caron G, Ermondi G. Lipophilicity, polarity, and hydrophobicity. In: Testa B, van de Waterbeemd H, editors. Comprehensive medicinal chemistry, vol. 5. 2nd ed. Oxford: Elsevier; 2006. p. 425-52.
14. alk. J Med Chem. 2005;48(9):3269-79.
15. Vistoli G, Pedretti A, Testa B. Partition coefficient and molecular flexibility: the concept of lipophilicity space. Chem Biodivers. 2009;6:1152-69.
16. Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36(7):1385-405. (Pubitemid 351929323)
17. Berellini G, Springer C, Waters NJ, Lombardo F. In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. J Med Chem. 2009;52(14):4488-95.
18. Caron G, Ermondi G, Gariboldi MB, Monti E, Gabano E, Ravera M, Osella D. The relevance of polar surface area (PSA) in rationalizing biological properties of several cis-diamminemalonatoplatinum(II) derivatives. ChemMedChem. 2009;4((10):1677-85.
19. Platts J, Oldfield SP, Reif MM, Palmucci A, Gabano E, Osella D. The RP-HPLC measurement and QSPR analysis of logP(o/w) values of several Pt(II) complexes. J Inorg Biochem. 2006;100(7):1199-207. (Pubitemid 43833465)
20. Heudi O, Mercier-Jobard S, Cailleux A, Allain P. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin. Biopharm Drug Dispos. 1999;20(2):107-16. (Pubitemid 29082204)
21. Coste F, Malinge JM, Serre L, Shepard W, Roth M, Leng M, et al. Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63Å resolution: hydration at the platinated site. Nucleic Acids Res. 1999;27(8):1837-46. (Pubitemid 29209625)
22. Coste F, Shepard W, Zelwer C. Description of ordered solvent molecules in a platinated decanucleotide duplex refined at 1.6Å resolution against experimental MAD phases. Acta Crystallogr Sect D. 2002;58:431-40. (Pubitemid 34248853)
23. Pastor M, Cruciani G, Watson KA. A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure-activity relationship analysis. J Med Chem. 1997;40:4089-102. (Pubitemid 28008403)
24. Caron G, Nurisso A, Ermondi G. How to extend the use of grid-based interaction energy maps from chemistry to biotopics. ChemMedChem. 2009;4(1):29-36.
25. Pagliara A, Khamis E, Trinh A, Carrupt PA, Tsai RS, Testa B. Structural properties governing retention mechanisms on RPHPLC stationary phase used for lipophilicity measurements. J Liq Chromatogr. 1995;18:1721-45.
26. McIntosh DP, Cooke RJ, McLachlan AJ, Daley-Yates PT, Rowland M. Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. J Pharm Sci. 1997;86(12):1478-83.
27. Welink J, Boven E, Vermorken JB, Gall HE, van der Vijgh WJ. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Clin Cancer Res. 1999;5(9):2349-58. (Pubitemid 29437313)
28. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol. 2003;56(2):205-13. (Pubitemid 36981436)
29. Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol. 2002;19(4):261-5. (Pubitemid 36016017)
30. Lombardo F, Obach R, Shalaeva MY, Gao F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem. 2002;45:2867-76. (Pubitemid 34627657)
31. Lombardo F, Obach R, Shalaeva MY, Gao F. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. J Med Chem. 2004;47:1242-50.